Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Pilatus Biosciences Announces Clinical Trial Collaboration with Roche to Evaluate PLT012 in First-in-Human Study in Hepatocellular Carcinoma
Thursday, August 14, 2025Pilatus Biosciences Inc a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers today announced a clinical trial collaboration with Roche
Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
Thursday, August 14, 2025The European Medicines Agency has granted orphan designation to rilzabrutinib a reversible covalent Brutons tyrosine kinase BTK inhibitor for IgGrelated disease IgGRD EMA grants orphan designation
Santhera signs agreement with GEN for the distribution of AGAMREE® (vamorolone) in Turkey
Wednesday, August 13, 2025Santhera Pharmaceuticalsannounces the signing of an exclusive agreement with Gen la ve Salk rnleri San ve Tic A GEN for the distribution and commercialization of AGAMREE vamorolone in Turkey for the treatment of Duchenne muscular dystrophy DMD in pat...
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
Wednesday, August 13, 2025AbbVietoday announced a million investment in its North Chicago Illinois manufacturing plant to expand domestic active pharmaceutical ingredient API production in the US This expansion is part of AbbVies previously
Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
Tuesday, August 12, 2025Novartis today announced positive topline results from its Phase III trials evaluating ianalumab VAY in adults with active Sjgrens disease Both trials met the primary endpoint of demonstrating statistically
PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
Tuesday, August 12, 2025Pfizer Incand Astellas Pharma Inc today announced positive topline results from the Phase EV clinical trial also known as KEYNOTE The EV study is evaluating PADCEV enfortumab vedotin
US NCI Sponsors Senhwa Biosciences' Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma
Friday, August 08, 2025Senhwa Biosciences Inc a new drug development company focusing on firstinclass therapeutics for oncology rare diseases and infectious diseases today announced that US National Cancer Institute NCI sponsors
AbOliGo Closes Oversubscribed Round to Accelerate Multiomic Research Tools and Appoints Proven Life Sciences Board
Thursday, August 07, 2025AbOliGo a biotechnology company pioneering high performance antibodyoligonucleotide conjugates AOCs today announced the successful close of an oversubscribed seed funding round
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
Thursday, August 07, 2025Starlight Therapeutics a wholly owned subsidiary of Lantern Pharma Inc NASDAQ LTRN today announced that the US Food and Drug Administration FDA has cleared its Investigational New Drug IND
ViruSure launches pioneering first-in-class viral contamination test for biopharmaceuticals using Oxford Nanopore technology
Thursday, August 07, 2025ViruSure a global leader in pathogen safety testing for biopharmaceuticals and Oxford Nanopore Technologies Oxford Nanopore LSE ONT the company behind a new generation of molecular sensing technology based on nanopores
